重新审视经典型霍奇金淋巴瘤肿瘤微环境中的IL-6表达
本研究在136例当代治疗的经典型霍奇金淋巴瘤(cHL)患者中,通过免疫组化检测肿瘤微环境(TME)中IL-6+白细胞和IL-6+HRS细胞,评估其与生存、免疫标志物及血清IL-6的关联。中位随访13.8年,发现IL-6+白细胞≥1%与更差的无事件生存和总生存相关,而IL-6+HRS细胞及血清IL-6水平与生存无关。
要点
- TME中IL-6+白细胞≥1%与cHL患者不良生存独立相关。
- IL-6+HRS细胞和血清IL-6水平与生存无显著关联。
- IL-6+白细胞与CD138+浆细胞、CD68+巨噬细胞等免疫标志物相关。
核心结论
- TME中IL-6+白细胞≥1%是cHL患者不良生存的独立预后因素,而IL-6+HRS细胞和血清IL-6水平与生存无关。
研究设计与样本
- 回顾性队列研究,纳入136例当代治疗的cHL患者,中位随访13.8年(范围0.59-15.9年),对诊断活检组织微阵列进行IL-6免疫组化。
主要发现
- IL-6+白细胞≥1%的患者(54/136)无事件生存更差(HR=3.58;95%CI 1.80-7.15),总生存更差(HR=6.71;95%CI 2.51-17.99)。
- 多变量Cox回归和倾向评分匹配分析调整已知不良预后协变量后,不良生存关联仍维持。
- IL-6+白细胞与IL-6+HRS细胞比例增加(P<.01)、CD138+浆细胞增加(P<.01)、CD68+巨噬细胞增加(P=.02)和类胰蛋白酶阳性肥大细胞增加(P<.01)相关。
- IL-6+HRS细胞与CD68+巨噬细胞增加(P=.03)、PD-L1+白细胞增加(P=.04)和PD-L1+HRS细胞增加(P<.01)相关。
- 血清IL-6水平与TME中IL-6表达无相关性。
临床怎么用
- 可考虑将TME中IL-6+白细胞≥1%作为cHL的预后评估指标,辅助识别高危患者。
- 血清IL-6水平不能替代TME中IL-6表达评估预后。
局限性
- 回顾性研究设计,样本量有限(n=136),需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Interleukin-6 (IL-6) can induce therapeutic resistance for several cancer agents currently used to treat classical Hodgkin lymphoma (cHL). We aimed to investigate whether the presence of IL-6+ leukocytes and IL-6+ Hodgkin-Reed-Sternberg (HRS) cells in the tumor microenvironment (TME) was associated with adverse survival outcomes, expression of other immune markers, and serum IL-6 levels. We used a contemporarily treated cohort (n = 136), with a median follow-up of 13.8 years (range, 0.59-15.9 years). We performed immunohistochemistry with an IL-6 antibody on tissue microarrays from diagnostic biopsies of cHL patients. Patients with IL-6+ leukocytes ≥1% (n = 54 of 136) had inferior event-free survival (hazard ratio [HR] = 3.58; 95% confidence interval [CI], 1.80-7.15) and overall survival (HR = 6.71; 95% CI, 2.51-17.99). The adverse survival was maintained in multivariate Cox regression and propensity score-matched analyses, adjusting for well-known poor-prognostic covariates. The presence of IL-6+ HRS cells and high serum IL-6 levels were not associated with survival. IL-6+ leukocytes correlated with increased proportions of IL-6+ HRS cells (P < .01), CD138+ plasma cells (P < .01), CD68+ macrophages (P = .02), and tryptase-positive mast cells (P < .01). IL-6+ HRS cells correlated with increased proportions of CD68+ macrophages (P = .03), programmed death-ligand 1-positive (PD-L1+) leukocytes (P = .04), and PD-L1+ HRS cells (P < .01). Serum-IL-6 lacked correlation with IL-6 expression in the TME. This is the first study highlighting the adverse prognostic impact of IL-6+ leukocytes in the TME in a cohort of contemporarily treated adult patients with cHL.
引用
- Gholiha AR, Hollander P, Glimelius I, et al. Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma. Blood Adv. 2021. PMID: 33720338. doi:10.1182/bloodadvances.2020003664
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。